CD8 (cluster of differentiation 8)

TCR clonality was increased in EBV+ cHL, with trend towards further increase in clonality in HIV+. Through a multiomic approach of a well-characterized, HIV-inclusive cHL cohort from one of the most resource-limited countries in the world, we were able to recapitulate known, and identify novel molecular differences by HIV and EBV status.

Our findings provide a reliable independent prognostic tool for OC and elucidate the intricate interplay between metabolic reprogramming and the immunosuppressive microenvironment. These results offer critical mechanistic insights for prognostic stratification and the development of personalized combinatorial immunotherapies in OC.

In vivo experiments confirmed that ESCO2 promotes tumor growth and shortens survival in mice. ESCO2 is a key regulatory gene affecting the development of CCA and plays an important role in CCA cell proliferation, which could be a new target for CCA diagnosis and treatment.

As these genes have extra-P-body functions, the score serves as a transcriptomic proxy for P-body component enrichment, not a direct measure of P-body activity. Despite this limitation, it offers a clinically useful tool for risk stratification and mechanistic hypotheses.

Camptothecin, CDK9 and multiple ion-channel inhibitors displayed selective efficacy in high-risk samples &lsqb;half-maximal inhibitory concentration (IC50) shift P<0.01]. Our study provided the first CHRG-based prognostic model that simultaneously captures tumor-intrinsic aggressiveness and immune-evasive capacity in BC, offering quantitative biomarkers and actionable therapeutic targets for precision oncology.

Importantly, findings from the clinical cohort confirmed that ITGA3 expression was positively correlated with CD206 and PD-L1, and negatively correlated with CD8 and CD19, supporting its role in shaping an immunosuppressive microenvironment. ITGA3 is a promising immune-related biomarker for predicting prognosis and therapeutic response in PDAC and may provide a potential target for personalized treatment strategies.

CRNDE 84aa is highly expressed in breast cancer and functions as a tumor antigen that activates anti-tumor immunity. This study suggests that lncRNA-encoded peptides represent a viable source of tumor antigens for immunologically "cold" tumors such as breast cancer, highlighting their potential as novel targets for immunotherapy.

We integrated multi-omics data from LUSC patients (n=494) across The Cancer Genome Atlas and Gene Expression Omnibus (GEO) database GSE73403 (n=69)...The CIGPS serves as a potent prognostic tool that elucidates the heterogeneous tumor immune microenvironment in LUSC. It holds significant promise for guiding risk assessment and informing personalized therapeutic strategies based on distinct molecular subtypes.

These findings provide translational validation for PD1-IL2v's mechanism, demonstrating selective intra-tumoral immune stimulation while minimizing Treg activation. This characterization identifies PD-1 receptor density and subset prevalence as critical factors for drug activity and represents potentially useful biomarkers for predicting patient responsiveness and guiding patient selection.

This review summarizes current understanding of how T cell dysfunction, epigenetic programming, and metabolic disruption interact in chronic HCV infection. Understanding these interconnected mechanisms may guide the development of novel therapeutic strategies that combine antiviral, immunomodulatory, and metabolic interventions to achieve durable immune restoration and improved clinical outcomes.

Recognising exhaustion as a context-dependent differentiation process reframes therapeutic strategies, in line with current evidence indicating that immune checkpoint blockade primarily acts by expanding and redirecting the TPEX pool rather than reversing terminal exhaustion. This framework integrates insights from chronic infection, tumour immunology, and tissue adaptation.

Peripheral immune profiling identifies an IL-6-centered and chemokine-centered inflammatory signature in ICI-My beyond background ICI exposure. Conventional cardiac biomarkers remain more informative than single cytokines for severity assessment in this cohort. IL-6R blockade appears biologically plausible and clinically feasible in selected steroid-refractory cases and warrants prospective evaluation.